A61P 21/06
Anabolic agents
Official title: Anabolic agents (androgens A61P5/26)
A61P21/06 (Anabolic agents) appears on 410 US grants and 685 published applications in this corpus.
Search patents in A61P- Granted patents
- 410
- Published applications
- 685
- Assignees
- 313
- Inventors
- 1,030
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 3 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 2 | 0 |
| 2000 | 7 | 0 |
| 2001 | 5 | 1 |
| 2002 | 4 | 6 |
| 2003 | 5 | 7 |
| 2004 | 2 | 18 |
| 2005 | 3 | 16 |
| 2006 | 5 | 17 |
| 2007 | 8 | 18 |
| 2008 | 12 | 27 |
| 2009 | 22 | 52 |
| 2010 | 25 | 28 |
| 2011 | 21 | 24 |
| 2012 | 19 | 36 |
| 2013 | 19 | 30 |
| 2014 | 19 | 35 |
| 2015 | 11 | 20 |
| 2016 | 16 | 43 |
| 2017 | 18 | 24 |
| 2018 | 23 | 28 |
| 2019 | 20 | 33 |
| 2020 | 28 | 35 |
| 2021 | 22 | 54 |
| 2022 | 25 | 44 |
| 2023 | 15 | 25 |
| 2024 | 22 | 29 |
| 2025 | 13 | 18 |
| 2026 | 13 | 17 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions comprising curcuminoids for use in the treatment of muscle soreness6 Oct 2026US 12,751,932 B2Givaudan SA
- Compositions comprising selective androgen receptor modulator compounds in combination with weight loss drugs and uses thereof for quality weight loss1 Sep 2026US 12,721,830 B2Veru Inc.
- Muscle quality improvement agent14 Jul 2026US 12,678,473 B2Ajinomoto Co., Inc.
- Creatine and/or creatinine compositions and related methods23 Jun 2026US 12,661,316 B2ThermoLife International, LLC
- Methods of treating myopathies with anti-pro/latent myostatin antibodies23 Jun 2026US 12,661,400 B2Scholar Rock, Inc.
- Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies20 Aug 2026US 2026/0242455 A1Scholar Rock, Inc.
- Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting30 Jul 2026US 2026/0216294 A1Atrogi AB
- Compositions comprising selective androgen receptor modulator compounds in combination with weight loss drugs and uses thereof for quality weight loss23 Jul 2026US 2026/0207543 A1Veru Inc.
- Antibodies to human gdf823 Jul 2026US 2026/0209327 A1Regeneron Pharmaceuticals, Inc.
- Ketone body and ketone body ester for reducing muscle breakdown16 Jul 2026US 2026/0199280 A1Tdeltas Limited
Most cited
By later US patents
- Methods for using tetanus toxin for beneficial purposes in animals (mammals)171US 7,494,661 B22009
- Medicament for treatment of Duchenne muscular dystrophy128US 6,653,467 B1JCR PHARMACEUTICAL CO., Ltd. · 2003
- ActRII receptor polypeptides, methods and compositions121US 7,709,605 B2Acceleron Pharma Inc. · 2010
- Transgenic non-human animals expressing a truncated activintype II receptor117US 6,891,082 B2The Johns Hopkins University School of Medicine · 2005
- Modified Fc molecules114US 7,442,778 B2Amgen Inc. · 2008